• Clinical Insights: May 27, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval PhexxiTM (lactic acid, citric acid and potassium bitartrate) Vaginal Gel – New Drug Approval – May 22, 2020 – Evofem Biosciences, Inc. announced that the U.S. Food… Read more »

  • Clinical Insights: May 19, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval QinlockTM (ripretinib) Tablets – New Drug Approval – May 15, 2020 – The U.S. Food and Drug Administration approved QinlockTM (ripretinib) tablets as the first new drug specifically… Read more »

  • Clinical Insights: May 12, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval RetevmoTM (selpercatinib) Capsules – New Drug Approval – May 8, 2020 – The U.S. Food and Drug Administration approved RetevmoTM (selpercatinib) capsules to treat three types of tumors… Read more »

  • Clinical Insights: May 5, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Darzalex FasproTM (daratumumab and hyaluronidase-fihj) Injection – New Drug Approval – May 1, 2020 –  The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food… Read more »

  • Clinical Insights: April 30, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Ongentys® (opicapone) Capsules – New Drug Approval – April 27, 2020 – Neurocrine Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral… Read more »

  • Clinical Insights: April 24, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval TukysaTM (tucatinib) – New Drug Approval – April 17, 2020 – As part of Project Orbis, the U.S. Food and Drug Administration approved TukysaTM (tucatinib) in combination with chemotherapy… Read more »

  • Clinical Insights: April 16, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Koselugo® (selumetinib) – New Drug Approval – April 10, 2020 – The U.S. Food and Drug Administration approved Koselugo® (selumetinib) for the treatment of pediatric patients, 2 years… Read more »

  • Clinical Insights: April 9, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval Sevenfact® (coagulation factor VIIa [recombinant]-jncw) – New Drug Approval – April 1, 2020 – The U.S. Food and Drug Administration approved Sevenfact® [coagulation factor VIIa (recombinant)-jncw] for the treatment and… Read more »

  • Clinical Insights: April 1, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Zeposia® (ozanimod) Capsules – New Drug Approval – March 26, 2020 – Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Zeposia® (ozanimod) 0.92… Read more »

  • Clinical Insights: March 24, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Isturisa® (osilodrostat) Tablets – New Orphan Drug Approval – March 6, 2020 – The U.S. Food and Drug Administration announced the approval of Isturisa® (osilodrostat)… Read more »